[go: up one dir, main page]

PL1706113T3 - Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu - Google Patents

Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu

Info

Publication number
PL1706113T3
PL1706113T3 PL04806731T PL04806731T PL1706113T3 PL 1706113 T3 PL1706113 T3 PL 1706113T3 PL 04806731 T PL04806731 T PL 04806731T PL 04806731 T PL04806731 T PL 04806731T PL 1706113 T3 PL1706113 T3 PL 1706113T3
Authority
PL
Poland
Prior art keywords
indol
dihydro
preparation
dipropylaminoethyl
hydrochloride
Prior art date
Application number
PL04806731T
Other languages
English (en)
Inventor
Venkatasubramanian Radhakrishnan Tarur
Dhananjay Govind Sathe
Harish Kashinath Mondkar
Rajesh Ganpat Bhopalkar
Samadhan Daulat Patil
Original Assignee
Usv Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Ltd filed Critical Usv Ltd
Publication of PL1706113T3 publication Critical patent/PL1706113T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL04806731T 2004-01-20 2004-07-16 Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu PL1706113T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN60MU2004 2004-01-20
PCT/IN2004/000214 WO2005067922A1 (en) 2004-01-20 2004-07-16 A process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-one hydrochloride
EP04806731A EP1706113B1 (en) 2004-01-20 2004-07-16 A process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-one hydrochloride

Publications (1)

Publication Number Publication Date
PL1706113T3 true PL1706113T3 (pl) 2009-07-31

Family

ID=34746665

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04806731T PL1706113T3 (pl) 2004-01-20 2004-07-16 Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu

Country Status (11)

Country Link
US (1) US7378439B2 (pl)
EP (1) EP1706113B1 (pl)
JP (1) JP2007518793A (pl)
KR (1) KR20060130108A (pl)
CN (1) CN1909901A (pl)
AT (1) ATE416766T1 (pl)
AU (1) AU2004313729A1 (pl)
CA (1) CA2548982A1 (pl)
DE (1) DE602004018386D1 (pl)
PL (1) PL1706113T3 (pl)
WO (1) WO2005067922A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009356855A1 (en) 2009-12-16 2012-08-09 Pharmathen S.A. Process for the preparation of Ropinirole and salts thereof
KR20120137373A (ko) 2010-04-30 2012-12-20 테이코쿠 팔마 유에스에이, 인코포레이티드 프로필아미노인단 경피 조성물
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SG10201912411RA (en) 2011-12-28 2020-02-27 Univ California Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10918607B2 (en) 2012-11-02 2021-02-16 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
CN103086946B (zh) * 2013-01-17 2018-10-23 浙江华海药业股份有限公司 一种盐酸罗匹尼罗纯化的方法
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970196B1 (en) 2013-03-15 2020-11-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
FI3102208T4 (fi) 2014-02-07 2024-09-23 Global Blood Therapeutics Inc 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
WO2017096230A1 (en) 2015-12-04 2017-06-08 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018227553A1 (zh) * 2017-06-16 2018-12-20 浙江华海立诚药业有限公司 盐酸罗匹尼罗的纯化方法
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
US5958965A (en) * 1996-08-27 1999-09-28 American Home Products Corporation 4-aminoethoxy indoles

Also Published As

Publication number Publication date
DE602004018386D1 (de) 2009-01-22
US20050159605A1 (en) 2005-07-21
EP1706113B1 (en) 2008-12-10
JP2007518793A (ja) 2007-07-12
WO2005067922A1 (en) 2005-07-28
CN1909901A (zh) 2007-02-07
ATE416766T1 (de) 2008-12-15
KR20060130108A (ko) 2006-12-18
EP1706113A1 (en) 2006-10-04
US7378439B2 (en) 2008-05-27
CA2548982A1 (en) 2005-07-28
AU2004313729A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
PL1706113T3 (pl) Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
ZA200706020B (en) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
HUP0302647A3 (en) Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide and their intermediates
WO2007124337A8 (en) Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
NZ516782A (en) Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
EP1201268A3 (en) Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
BG107468A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
WO2004005262A3 (en) New neuropeptide y y5 receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
MY153719A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200509920A (en) Imidazole derivatives
WO2007081995A3 (en) Urotensin ii receptor antagonists
MY147474A (en) 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1
AU2005313582A8 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
TW200616952A (en) Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride
UA97648C2 (ru) N-(2-гидроксиэтил)-n-метил-4-(хинолин-8-ил(1-(тиазол-4-илметил)пиперидин-4-илиден)метил)бензамид, способ его получения (варианты), фармацевтическая композиция и его применение для подавления боли или для лечения депрессии, тревожности или болезни паркинсона
WO2007074386A3 (en) A novel process for synthesis of itopride and it’s novel intermediate-n-(4-hydroxybenzyl)-3,4-dimethoxybenzamide
AU2003235814A8 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile